Published in J Biol Chem on May 04, 2011
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev (2011) 1.93
Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer (2012) 1.79
Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol (2012) 1.55
Identification of DES1 as a vitamin A isomerase in Müller glial cells of the retina. Nat Chem Biol (2012) 1.35
Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. J Biol Chem (2012) 1.05
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03
Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. Mol Cell Biol (2013) 0.93
Genetic loci associated with circulating levels of very long-chain saturated fatty acids. J Lipid Res (2014) 0.89
The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother (2014) 0.88
Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochem Cell Biol (2012) 0.85
Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue. Biochem Pharmacol (2015) 0.84
C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLoS One (2013) 0.84
Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells. J Lipid Res (2012) 0.83
Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res (2014) 0.83
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther (2015) 0.82
Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis (2012) 0.81
Novel chemotherapeutic drugs in sphingolipid cancer research. Handb Exp Pharmacol (2013) 0.80
Sphingolipids in colon cancer. Biochim Biophys Acta (2013) 0.80
Dihydroceramide desaturase knockdown impacts sphingolipids and apoptosis after photodamage in human head and neck squamous carcinoma cells. Anticancer Res (2013) 0.80
Dihydroceramides: From Bit Players to Lead Actors. J Biol Chem (2015) 0.80
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. Biochim Biophys Acta (2015) 0.78
Vitamin E metabolite 13'-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice. Free Radic Biol Med (2016) 0.77
Fenretinide induces ubiquitin-dependent proteasomal degradation of stearoyl-CoA desaturase in human retinal pigment epithelial cells. J Cell Physiol (2014) 0.77
Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: a California Cancer Consortium Trial. Clin Cancer Res (2017) 0.75
Gamma-tocotrienol profoundly alters sphingolipids in cancer cells by inhibition of dihydroceramide desaturase and possibly activation of sphingolipid hydrolysis during prolonged treatment. J Nutr Biochem (2017) 0.75
Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol (2008) 12.34
Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer (2004) 5.63
Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods (2006) 4.31
Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta (2006) 3.10
Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J Biol Chem (1993) 1.63
Identification and characterization of a sphingolipid delta 4-desaturase family. J Biol Chem (2002) 1.60
gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci U S A (2004) 1.52
Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol (2006) 1.43
Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem (2007) 1.38
Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J Biol Chem (1997) 1.37
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther (2008) 1.37
Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett (2009) 1.35
N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res (2001) 1.32
Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem (2006) 1.24
Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis (2001) 1.24
DES2 protein is responsible for phytoceramide biosynthesis in the mouse small intestine. Biochem J (2004) 1.19
Dihydroceramide hinders ceramide channel formation: Implications on apoptosis. Apoptosis (2006) 1.16
Identification of the human sphingolipid C4-hydroxylase, hDES2, and its up-regulation during keratinocyte differentiation. FEBS Lett (2004) 1.15
Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer (1998) 1.09
Conversion of dihydroceramide into ceramide: involvement of a desaturase. Biochem J (1997) 1.06
The CLN9 protein, a regulator of dihydroceramide synthase. J Biol Chem (2005) 1.06
Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res (2004) 1.06
Dihydroceramide desaturase activity is modulated by oxidative stress. Biochem J (2010) 1.05
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res (2008) 1.04
4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res (2006) 1.04
Synthesis and biological activity of a novel inhibitor of dihydroceramide desaturase. ChemMedChem (2008) 1.03
Synthesis of cyclopropene analogues of ceramide and their effect on dihydroceramide desaturase. J Org Chem (2003) 1.01
Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol (2007) 1.01
Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. Br J Cancer (2009) 1.00
The product of the MLD gene is a member of the membrane fatty acid desaturase family: overexpression of MLD inhibits EGF receptor biosynthesis. Biochemistry (1997) 0.99
Dihydroceramide desaturase. Methods Enzymol (2000) 0.96
Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in primary cultured cerebellar neurons. Mol Pharmacol (2004) 0.92
Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther (2007) 0.84
Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl (1993) 0.84
Preparation of intact microsomes from cultured mammalian H4IIE cells. J Pharmacol Toxicol Methods (2005) 0.83
Chemoprevention of breast cancer with fenretinide. Drugs (2001) 0.80
Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs. Bioorg Med Chem Lett (2006) 0.79
Irreversible inhibition of CYP2D6 by (-)-chloroephedrine, a possible impurity in methamphetamine. Drug Metab Dispos (2002) 0.78
Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol (2008) 12.34
Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer (2004) 5.63
The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem (2002) 4.52
Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods (2006) 4.31
Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell (2012) 3.23
Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature (2007) 3.13
The complex life of simple sphingolipids. EMBO Rep (2004) 3.10
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res (2004) 2.78
Bioactive sphingolipids: metabolism and function. J Lipid Res (2008) 2.73
Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta (2002) 2.69
An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol (2010) 2.33
Many ceramides. J Biol Chem (2011) 2.31
Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta (2008) 2.25
De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem (2002) 2.24
The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal (2007) 2.16
PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem (2002) 2.11
The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J (2003) 2.10
Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol (2004) 2.06
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab (2009) 2.00
Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes (2006) 1.91
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem (2004) 1.84
Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J (2005) 1.83
Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J (2009) 1.82
Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J (2008) 1.78
Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature (2005) 1.76
Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem (2003) 1.76
Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem (2003) 1.75
Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem (2002) 1.74
Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res (2010) 1.72
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J (2008) 1.71
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta (2006) 1.65
The extended family of neutral sphingomyelinases. Biochemistry (2006) 1.63
Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal (2009) 1.62
Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem (2005) 1.61
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem (2007) 1.61
Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim Biophys Acta (2004) 1.61
Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J (2005) 1.57
Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J (2012) 1.57
Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J (2008) 1.56
Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem (2008) 1.55
Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther (2007) 1.55
Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem (2004) 1.52
Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem (2005) 1.51
Activation of acid sphingomyelinase by protein kinase Cdelta-mediated phosphorylation. J Biol Chem (2007) 1.49
Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem (2003) 1.47
The mechanism of membrane targeting of human sphingosine kinase 1. J Biol Chem (2005) 1.44
Necessary role for the Lag1p motif in (dihydro)ceramide synthase activity. J Biol Chem (2006) 1.43
Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids. FEBS Lett (2009) 1.43
The sphingolipid pathway regulates Pkc1 through the formation of diacylglycerol in Cryptococcus neoformans. J Biol Chem (2004) 1.42
BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J Biol Chem (2003) 1.39
Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem (2007) 1.38
Involvement of sphingoid bases in mediating reactive oxygen intermediate production and programmed cell death in Arabidopsis. Cell Res (2007) 1.38
Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem (2007) 1.36
Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol (2008) 1.35
The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol (2005) 1.33
Translational aspects of sphingolipid metabolism. Trends Mol Med (2007) 1.31
Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J Biol Chem (2003) 1.31
Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. Neuromolecular Med (2010) 1.30
Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB J (2006) 1.30
Identification and quantification of apo-lycopenals in fruits, vegetables, and human plasma. J Agric Food Chem (2010) 1.30
Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol (2008) 1.30
Disruption of ceramide synthesis by CerS2 down-regulation leads to autophagy and the unfolded protein response. Biochem J (2009) 1.29
A mitochondrial pool of sphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochem J (2005) 1.28
Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function. Biochim Biophys Acta (2006) 1.28
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther (2007) 1.27
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet (2010) 1.25
Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids. J Biol Chem (2005) 1.24
Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther (2006) 1.24
Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis. J Biol Chem (2007) 1.24
Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem (2006) 1.24
Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem (2003) 1.24
Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J Biol Chem (2005) 1.23
Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism. J Lipid Res (2010) 1.23